The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform

G M Farrow - One of the best experts on this subject based on the ideXlab platform.

  • Small Cell Anaplastic Carcinoma of the Prostate: A Clinical, Pathological and Immunohistological Study of 27 Patients
    The Journal of Urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    AbstractBecause small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months)...

  • Small cell Anaplastic Carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.
    The Journal of urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    Because small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months). All tumors with tissue available for immunohistochemical staining reacted positive for neuron-specific enolase, indicating that small cell Anaplastic Carcinoma of the prostate is most likely a neuroendocrine neoplasm. No tumor stained positive for either prostatic acid phosphatase or prostate specific antigen. Pathologically, small cell Anaplastic Carcinoma of the prostate appears to be similar to oat cell Carcinoma of the lung. This series of 27 patients emphasizes that small cell Anaplastic Carcinoma of the prostate is highly malignant, is frequently of advanced stage at presentation, responds poorly to antiandrogen therapy and has a poor prognosis.

J E Oesterling - One of the best experts on this subject based on the ideXlab platform.

  • Small Cell Anaplastic Carcinoma of the Prostate: A Clinical, Pathological and Immunohistological Study of 27 Patients
    The Journal of Urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    AbstractBecause small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months)...

  • Small cell Anaplastic Carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.
    The Journal of urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    Because small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months). All tumors with tissue available for immunohistochemical staining reacted positive for neuron-specific enolase, indicating that small cell Anaplastic Carcinoma of the prostate is most likely a neuroendocrine neoplasm. No tumor stained positive for either prostatic acid phosphatase or prostate specific antigen. Pathologically, small cell Anaplastic Carcinoma of the prostate appears to be similar to oat cell Carcinoma of the lung. This series of 27 patients emphasizes that small cell Anaplastic Carcinoma of the prostate is highly malignant, is frequently of advanced stage at presentation, responds poorly to antiandrogen therapy and has a poor prognosis.

C G Hauzeur - One of the best experts on this subject based on the ideXlab platform.

  • Small Cell Anaplastic Carcinoma of the Prostate: A Clinical, Pathological and Immunohistological Study of 27 Patients
    The Journal of Urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    AbstractBecause small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months)...

  • Small cell Anaplastic Carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.
    The Journal of urology, 1992
    Co-Authors: J E Oesterling, C G Hauzeur, G M Farrow
    Abstract:

    Because small cell Anaplastic Carcinoma of the prostate is an uncommon tumor, it has remained a poorly defined entity. To elucidate further the clinical, pathological and immunohistochemical characteristics of this cancer the 27 patients who presented to the Mayo Clinic from 1960 to 1990 were reviewed. Of these patients 18 (67%) presented with pure small cell Anaplastic Carcinoma, and 9 (33%) were diagnosed with small cell Anaplastic Carcinoma and adenoCarcinoma of the prostate. Twenty-six patients (96%) had either stage C or D disease at the time of diagnosis. Two patients presented with a paraneoplastic syndrome, including 1 man with inappropriate antidiuretic hormone secretion and 1 who suffered from thyroxine intoxication. Of 24 men with long-term followup 22 (92%) died of small cell Anaplastic Carcinoma of the prostate despite antiandrogen therapy and the remaining 2 are alive with active, progressive disease. The median survival time following diagnosis was 17.1 months (range 2 to 90 months). All tumors with tissue available for immunohistochemical staining reacted positive for neuron-specific enolase, indicating that small cell Anaplastic Carcinoma of the prostate is most likely a neuroendocrine neoplasm. No tumor stained positive for either prostatic acid phosphatase or prostate specific antigen. Pathologically, small cell Anaplastic Carcinoma of the prostate appears to be similar to oat cell Carcinoma of the lung. This series of 27 patients emphasizes that small cell Anaplastic Carcinoma of the prostate is highly malignant, is frequently of advanced stage at presentation, responds poorly to antiandrogen therapy and has a poor prognosis.

Fred R. Hirsch - One of the best experts on this subject based on the ideXlab platform.

Kazuhiro Hanazaki - One of the best experts on this subject based on the ideXlab platform.

  • Mucinous cystadenoCarcinoma of the pancreas with Anaplastic Carcinoma: A case report and review of the literature
    Molecular and clinical oncology, 2016
    Co-Authors: Masaya Munekage, Tsutomu Namikawa, Takuhiro Kohsaki, Sunao Uemura, Hiroyuki Kitagawa, Kazuhiro Hanazaki
    Abstract:

    Few reports of mucinous cystic neoplasm (MCN) in association with Anaplastic Carcinoma exist. The present study reported an unusual case of a 25-year-old female exhibiting large pancreatic MCN with Anaplastic Carcinoma. Notably, the patient was a Jehovah's Witness and therefore refused any blood transfusions. Preoperative diagnosis was invasive pancreatic MCN measuring 12.5 cm with ascites. Distal pancreatectomy was performed in combination with splenectomy and partial resection of the transverse colon. Intraoperative estimated blood loss was 400 ml, therefore a blood transfusion was not required. The patient had an uneventful postoperative course. The pathological diagnosis was mucinous cystadenoCarcinoma of the pancreas with Anaplastic Carcinoma. Although the patient underwent postoperative adjuvant chemotherapy with gemcitabine and oral fluoropyrimidine (S-1), recurrence with peritoneal dissemination was detected 20 months following surgery and the patient succumbed to the recurrence 32 months following surgery. To the best of our knowledge, this is the first case report of MCN with Anaplastic Carcinoma of the pancreas in a Jehovah's Witness patient undergoing pancreatic surgery.

  • clinical analysis of primary Anaplastic Carcinoma of the small intestine
    World Journal of Gastroenterology, 2009
    Co-Authors: Tsutomu Namikawa, Kazuhiro Hanazaki
    Abstract:

    Primary Anaplastic Carcinoma is a rare variant of small intestinal cancer. Most reports of primary Anaplastic Carcinoma of the small intestine are isolated case reports, therefore the clinicopathological features, therapeutic management, and surgical outcome of this tumor type remain unclear. This review analyzes the available clinical characteristics of primary Anaplastic Carcinoma of the small intestine and investigates key differences from differentiated adenoCarcinoma of the small intestine. A Medline search was performed using the keywords ‘small intestine’ and ‘Anaplastic Carcinoma’ or ‘undifferentiated Carcinoma’. Additional articles were obtained from references within the papers identified by the Medline search. The literature revealed a poor prognosis for patients who underwent surgical resection for Anaplastic Carcinoma of the small intestine, which gave a 3-year overall survival rate of 10.8% and a median survival time of 5.0 mo. The literature suggests that Anaplastic Carcinoma is markedly more aggressive than differentiated adenoCarcinoma of the small intestine. Surgical resection with the aim of complete tumor removal provides the only beneficial therapeutic option for patients with Anaplastic Carcinoma of the small intestine, because chemotherapy and radiation therapy have no significant effect on the rate of survival. However, despite complete tumor resection, most patients with Anaplastic Carcinoma of the small intestine are at great risk of disease recurrence. Multicenter clinical trials are expected to provide additional therapeutic strategies and establish the efficacy of multimodality adjuvant therapy. This report also highlights the importance of a systematic diagnostic approach for Anaplastic Carcinoma of the small intestine.